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Despite great advances in understanding the mech-
anisms underlying blood production, lineage specifi-
cation at the level of multipotent progenitors (MPPs)
remains poorly understood. Here, we show that
MPP2 and MPP3 are distinct myeloid-biased MPP
subsets that work together with lymphoid-primed
MPP4 cells to control blood production. We find
that all MPPs are produced in parallel by hematopoi-
etic stem cells (HSCs), but with different kinetics
and at variable levels depending on hematopoietic
demands. We also show that the normally rare
myeloid-biased MPPs are transiently overproduced
by HSCs in regenerating conditions, hence support-
ingmyeloid amplification to rebuild the hematopoiet-
ic system. This shift is accompanied by a reduction
in self-renewal activity in regenerating HSCs and
reprogramming of MPP4 fate toward the myeloid
lineage. Our results support a dynamic model of
blood development in which HSCs convey lineage
specification through independent production of
distinct lineage-biased MPP subsets that, in turn,
support lineage expansion and differentiation.
INTRODUCTION
Blood production is a highly regulated process that tailors the
output of the myeloid and lymphoid lineages based on hemato-
poietic demands and the needs of the organism (Ema et al.,
2014). Blood development starts with rare self-renewing he-
matopoietic stem cells (HSCs), which produce a series of
increasingly more abundant and lineage-committed progenitor
cells, ultimately giving rise to all types of mature blood cells.Although the overall structure of the blood system and its hierar-
chical nature is well established, many questions still remain
regarding how HSCs specify lineage fate in non-self-renewing
multipotent progenitors (MPPs) prior to the generation of line-
age-committed progenitors and the separation of the myeloid
and lymphoid lineages.
HSCs are defined functionally by their ability to serially engraft
transplanted recipients and regenerate the entire blood system.
This unique property is used to directly measure HSC self-
renewal activity and to identify HSCs based on phenotypic
markers. In the mouse, HSCs are found in the Lin/Sca-1+/c-
Kit+ (LSK) fraction of the bone marrow (BM) and are usually
defined as CD150+/CD48 LSK cells (Kiel et al., 2005), although
other surface markers can be used to enrich for more quiescent
and/or functionally distinct subsets including Flk2, CD34, EPCR,
rhodamine, the other SLAM markers CD229 and CD244, and
CD41 (Wilson et al., 2008; Kent et al., 2009; Oguro et al.,
2013; Yamamoto et al., 2013; Miyawaki et al., 2015). Transplan-
tation experiments have shown that markers enriching for
the most quiescent and metabolically inert HSC subsets will
directly favor engraftment and self-renewal activity (Pietras
et al., 2011; Kohli and Passegue´, 2014). Single cell transplanta-
tion experiments have further demonstrated that even HSCs
with identical surface phenotypes are heterogeneous in their
engraftment behaviors, with different stabilities over time and
variable degrees of myeloid versus lymphoid lineage output
(Dykstra et al., 2007; Yamamoto et al., 2013). Several models
are currently proposed to explain this heterogeneity, including
the sequential loss of lineage potential in differentiating HSCs
(Adolfsson et al., 2005), the existence of long-lived myeloid
bypass pathways (Yamamoto et al., 2013), and the presence
of functionally distinct clones of lineage-biased HSCs with
different biological activities and hard-wired lineage potentials
(Muller-Sieburg et al., 2004; Dykstra et al., 2007). However,
it remains unclear whether the behavior of transplanted HSCs
accurately reflects steady-state hematopoiesis and HSC func-
tion in native conditions. In fact, it is possible that the distinctCell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc. 35
Figure 1. Reinvestigating MPP Subsets
(A) Table showing overlap of MPP subsets with
previously published definitions.
(B) Representative gating strategy used to identify
and isolate HSCLT, HSCST, MPP2, MPP3, and
MPP4 based on expression of Flk2, CD48, and
CD150 in BM LSK.
(C) Representative histograms of Sca-1, CD34,
ESAM, and CD41 expression in the indicated
LSK subsets.
(D) Average percentage in BM LSK and
absolute numbers of each population (8 mice/
group).
(E) Wright-Giemsa staining of the indicated LSK
subsets.
Results are expressed as mean ± SD.behaviors exhibited by single transplanted HSCs represent
reversible activities that span a continuum of surface markers
and activation states. The identification of MPP1 as a meta-
bolically active subset of HSCs directly supports this idea
(Cabezas-Wallscheid et al., 2014). Moreover, two exciting
lineage tracking studies marking HSCs in their native environ-
ment using either sleeping beauty transposons (Sun et al.,
2014) or Tie2-Cre endogenous labeling (Busch et al., 2015)
have recently shown a limited contribution of HSCs to steady-
state hematopoiesis and, conversely, a major role for MPPs
and lineage-committed progenitors to ongoing blood
production.
MPPs are currently a poorly defined hematopoietic compart-
ment, and the term itself is used rather indiscriminately to refer
to cells within the LSK fraction that have limited to no engraft-
ment ability in transplantation experiments. The best-character-
ized and most abundant MPP subset is defined as Flk2+ LSK
cells and is now considered as a fully multipotent but lineage-
biased population, with low megakaryocyte/erythroid (MegE)
and high lymphoid potentials (Adolfsson et al., 2005; Forsberg36 Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc.et al., 2006; Boyer et al., 2011; Buza-
Vidas et al., 2011). In fact, the top 25%
of the most highly expressing Flk2+ LSK
cells have been called lymphoid-primed
MPPs or LMPPs (Adolfsson et al.,
2005). Recently, two other MPP subsets
have been described in the Flk2 LSK
fraction and termed MPP2 and MPP3,
with Flk2+ LSK cells re-named MPP4
(Wilson et al., 2008). Although preliminary
investigations suggest that MPP2 and
MPP3 have myeloid-biased outputs
(Cabezas-Wallscheid et al., 2014), little
is known about their biological function.
Here, we directly compared the function
of MPP2, MPP3, and MPP4 in blood
production at steady state and in
regenerating conditions following HSC
transplantation. We propose a model
wherein HSCs produce in parallel distinct
subsets of lineage-biased MPPs, which
together coordinate the output of themyeloid and lymphoid lineages in response to hematopoietic
demands.
RESULTS
Lineage-Biased MPP Subsets
Many names and phenotypic definitions are currently used to
describe the spectrum of MPP subsets present in the mouse
LSK BM compartment (Figure 1A). One of the most broadly
applicable schemes separates the most quiescent HSCs
(CD34/Flk2/CD150+/CD48 LSK) from themore metabolically
active MPP1 (CD34+/Flk2/CD150+/CD48 LSK) and divides
MPPs into three further distinct subsets: MPP2 (Flk2/CD150+/
CD48+ LSK), MPP3 (Flk2/CD150/CD48+ LSK), and MPP4
(Flk2+/CD150/CD48+/ LSK) (Figure 1B) (Wilson et al., 2008;
Cabezas-Wallscheid et al., 2014). Importantly, these populations
overlap with other MPP definitions based on reporter gene com-
binations and different surface markers (Arinobu et al., 2007;
Akala et al., 2008; Oguro et al., 2013). Because our focus was
on MPP biology, we did not use CD34 separation and referred
Figure 2. Coexistence of Functionally
Distinct MPP Subsets
(A) Proliferation rates. Cells were pulsed for 1 hr
with BrdU before analysis (nR 3).
(B) Expansion in liquid culture. Cells were counted
every other day (n = 2).
(C) Methylcellulose clonogenic assays and pic-
tures of representative colonies. Single cells were
used to measure plating efficiency and colony-
forming unit (CFU) activity (nR 3).
(D) Meg differentiation potential in collagen-based
MegaCult assays (n = 2). mCFU-Meg: small
mature colony of%6 Meg; eCFU-Meg: large early
colony ofR6 Meg.
(E) CFU-S assays. Representative photograph of
spleen colonies obtained after transplantation of
the indicated populations in lethally irradiated
mice (n = 2). CFU-S frequency is given at day 12.
(F) Clonogenic B cell differentiation potential on
OP9/IL-7 stromal cells. Single, 10, and 50 cells
were grown for 16 days and analyzed by flow
cytometry for production of CD19+ B cells (10–34
wells/cell dose).
Results are expressed as mean ± SEM;Bp < 0.05,
*p < 0.001.
See also Figure S1.to the combination of HSC and MPP1 as HSCLT. We also
included an additional sub-population of LSK cells defined as
CD34+/Flk2/CD150/CD48 LSK (Figure 1B) that we named
short-term HSCs (HSCST) and referred to the combination of
HSCLT and HSCST as HSCs.
Both MPP2 and MPP3 showed low surface expression of
Sca-1 compared to HSCs and MPP4 and, like MPP4, expressed
high levels of CD34 (Figure 1C). However, unlike MPP4, they also
expressed the HSC markers ESAM (Ooi et al., 2009) and, to
various degrees, CD41 (Figure 1C). In steady-state conditions,
both MPP2 and MPP3 were as rare as HSCs (Figure 1D), and
were morphologically undistinguishable from other LSK popula-
tions (Figure 1E). As expected, short-term bromodeoxyuridine
(BrdU) incorporation experiments showed higher proliferation
rates in MPP2 and MPP3 than in HSCs, which were in the rangeCell Stem Cell 17,of MPP4 (Figure 2A) (Wilson et al., 2008).
Liquid culture experiments confirmed
similar expansion rates from all three
MPP subsets, which distinguished them
from the long-lived HSCs and growth-
restricted common myeloid progenitors
(CMPs) and granulocyte/macrophage
progenitors (GMPs) (Figure 2B). Flow
cytometry analyses for Mac-1 and
FcgR myeloid differentiation markers
also demonstrated persistence of granu-
locyte/macrophage (GM) potential in
cultured MPP2 and MPP3 compared to
the transient myeloid output observed
with MPP4 (Figure S1A). In clonogenic
methylcellulose assays, both MPP2 and
MPP3 gave rise to all myeloid lineages
but with plating efficiency and patternof differentiation distinct from HSCs, MPP4, and myeloid pro-
genitors (Figure 2C). Strikingly, MPP3 showed a dominant GM
output, whereasMPP2 displayed extensiveMeg potential, which
was confirmed in collagen-based MegaCult assays (Figure 2D).
Spleen colony-forming unit (CFU-S) assays also indicated
similarly strong erythroid potential from both MPP2 and MPP3,
which was intermediate to that of HSCs and MPP4/CMPs (Fig-
ure 2E). When cultured on OP9/IL-7 to assess B cell potential,
bothMPP2 andMPP3 generated CD19+ B cells, but with kinetics
that again were intermediary between HSCLT and MPP4 (Fig-
ure S1B). Furthermore, single cell analyses revealed 8-fold
lower B cell clonogenic potential in MPP2 and MPP3 compared
to MPP4, and a unique ability to produce B/myeloid mix colonies
(Figures 2F and S1C). Similarly, when cultured on OP9-DL1 stro-
mal cells for T cell potential, both MPP2 and MPP3 produced35–46, July 2, 2015 ª2015 Elsevier Inc. 37
Figure 3. Specific Lineage Biases in MPP
Subsets
(A) Experimental scheme for the in vivo lineage
tracking experiments. GFP+ populations were
transplanted into sub-lethally irradiated recipients
and followed over time for their reconstitution
activity and lineage potential in PB.
(B) Platelet chimerism following transplantation of
2,000 (upper graphs) or 500 (lower graphs) cells
of the indicated donor GFP+ population. Each line
represents individual mice (2–4 mice/group).
(C) Nucleated cell chimerism (upper graphs) and
percent of donor-derived Mac1+ myeloid cells
(lower graphs) following transplantation of 2,000
cells of the indicated donor GFP+ population.
Each line represents individual mice (2–4 mice/
group).
See also Figure S2.CD25+/CD44+ and CD25+/CD44 immature thymocytes with
kinetics intermediary between HSCLT and MPP4 (Figure S1D).
Taken together, these in vitro analyses indicate that MPP2 and
MPP3 retain full multipotentiality but display specific myeloid
biases (i.e., Meg for MPP2 and GM for MPP3) analogous to the
lymphoid bias exhibited by MPP4. In addition, based on surface
marker expression, MPP2 could be positioned upstream of
Pre-MegE and MPP3 upstream of Pre-GM (Figure S1E) (Pronk
et al., 2007), thereby establishing a connection between these
MPP subsets and myeloid progenitors committed to their
dominant lineage fate, similar to the link between MPP4 and
Flk2-expressing common lymphoid progenitors (CLPs).
Functional Validation
To further demonstrate the intrinsic myeloid bias of these
two MPP subsets, we transplanted HSCLT, HSCST, MPP2,
MPP3, and MPP4 isolated from b-actin-Gfp mice into sub-38 Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc.lethally irradiated recipients and followed
their multilineage output in peripheral
blood (PB) as we have previously done
(Forsberg et al., 2006) (Figure 3A). These
lineage-tracking experiments confirmed
that MPP2 and MPP3 were both devoid
of self-renewal potential (Santaguida
et al., 2009; Cabezas-Wallscheid et al.,
2014) because, like MPP4, they only ex-
hibited short-term myeloid reconstitution
ability (%1 months) in contrast to the
sustained potential displayed by HSCs
(Figure 3B). Interestingly, differences in
HSCLT and HSCST reconstitution activity
were only revealed by transplanting a
low number of cells (Figure 3B) and
tracking the persistence of myeloid
output for up to 4 months (Figure S2A).
In fact, HSCST behaved similarly to the
previously described intermediate-term
HSCs (ITRC) (Benveniste et al., 2010).
Importantly, these lineage-tracking ex-periments directly showed the multipotent nature of MPP2 and
MPP3, and their ability to generate low levels of B and T cells
in vivo (Figure S2B). They also highlighted the considerable
but transient ability of MPP2 to produce platelets (Figures 3B
and S2C), and the extensive GM potential of both MPP2 and
MPP3, which were able to maintain production of mature
myeloid cells for 2 weeks longer than MPP4 (Figure 3C). Taken
together, these in vivo experiments confirm that MPP2 and
MPP3 are two myeloid-biased MPP subsets that are functionally
distinct from the lymphoid-primed MPP4.
Molecular Validation
To understand how MPP2 and MPP3 fit into the hematopoietic
continuum, we conducted genome-wide microarray analyses.
Hierarchical clustering based on gene signatures derived from
the 1,000 most highly differentially expressed genes in HSCLT
and GM lineage-committed cells (Figures S3A and S3B;
Figure 4. Molecular Biases in MPP Subsets
(A) Hierarchical clustering analysis based on the
1,000 most highly expressed genes in HSCLT and
GM lineage-committed cells (GMP, Gr precursors:
pre Gr; Gr). *Indicates one MPP4 sample clus-
tering independently.
(B) Principal component (PC) analysis of the
microarray results shown in (A). Axis labels indi-
cate the primary gene signature driving each PC
separation.
(C) Individual gene signatures representing the
1,000 most highly expressed genes in MPP2,
MPP3, and MPP4 relative to the other two
populations.
(D) Gene ontology (GO) analyses and examples of
the gene signatures shown in (C).
See also Figure S3 and Tables S1, S2, S3, and S4.Table S1), divided the hematopoietic hierarchy into three main
groups: (1) highly immature HSCLT and HSCST; (2) multipotent
progenitors including MPP2, MPP3, MPP4, and early myeloid-
committed CMPs; and (3) GM lineage-committed cells including
GMPs, Gr precursors (Pre Gr), and Gr (Figure 4A). Interestingly,
principal component (PC) and gene ontology (GO) analyses
identified inflammation genes as main drivers of PC1, which
set apart the entire GM-committed myeloid differentiation axis,
whereas cell-cycle genes drove PC2, which segregated HSCST
from HSCLT, and metabolism genes PC3, which separated
MPP2 and MPP3 from MPP4 (Figures 4B and S3C; Table S2).
Moreover, GO analyses performed on gene signatures repre-
senting the 1,000 most highly differentially expressed genes in
each MPP relative to the other two underscored their unique
molecular features (Figures 4C and 4D; Table S3). As expected,
the MPP4 signature was enriched in lymphoid differentiation
genes, whereas the MPP3 signature was enriched for myeloid
differentiation genes and MPP2 signature for genes related
to hemostasis. Consistently, MPP2 showed features of anCell Stem Cell 17,active MegE transcription program, with
high expression levels of Gfi1b, Gata1,
and Fog1 (Figure S3D). These distinct
gene expression signatures allowed
recognition of MPP2, MPP3, and MPP4
in other published gene expression
datasets (Table S4). Taken together,
these molecular studies corroborate
our functional analyses by positioning
the rare myeloid-biased MPP2 and
MPP3 together with the more abundant
lymphoid-primed MPP4 in a multipotent
compartment located downstream of
HSCs and upstream of the already line-
age-committed myeloid and lymphoid
progenitors.
Hierarchical Organization
To confirm the hierarchy between MPP2,
MPP3, and MPP4, we first performed
short-term in vitro differentiation experi-
ments, and followed changes in earlystem and progenitor surface marker expression by flow cytom-
etry (Figures 5A and S4A). Whereas robust c-Kit and Sca-1
expression allowed tracking of LSK differentiation, the lack of
Flk2 induction in vitro or its quick downregulation following
exposure to Flt-3 ligand did not permit the separation of
newly generated MPP3 and MPP4. In both HSCLT and HSCST
cultures, we observed a persistent LSK compartment, which
first produced MPP2 and then MPP3/4 (Figure 5A). In contrast,
in MPP cultures, the LSK compartment quickly differentiated
into c-Kit+/Sca-1 myeloid progenitors and c-Kit/Sca-1
mature myeloid cells, with the few remaining LSK cells preser-
ving their initial identity despite some fluctuation in marker
expression (Figure S4A). Although these in vitro results estab-
lish that MPP2 is the first MPP subset produced by differenti-
ating HSCs, they do not distinguish whether MPP2 then
make MPP3/4, or whether the other MPP subsets are directly
generated from HSCs but with slower kinetics. To further
clarify this relationship, we took advantage of mice lacking
the thrombopoietin receptor (Mpl) gene (Gurney et al., 1994)35–46, July 2, 2015 ª2015 Elsevier Inc. 39
Figure 5. Hierarchical Organization and
Molecular Priming
(A) Differentiation in vitro. Representative FACS
plots showing HSCLT and HSCST differentiation
kinetics in myeloid conditions (n = 2).
(B) Size of the indicated BM populations inMpl/
and littermate control mice (3 mice/group).
(C) Differentiation in vivo. Representative FACS
plots of LSK and myeloid progenitor output
10 days following transplantation of 5,000 cells of
the indicated donor population (3 mice/group).
(D) Fluidigm gene expression analyses at steady
state. Results are expressed as mean (bar) and
individual fold differences compared to HSCLT
(8–12 pools of 11 cells/population; nd, not
detectable).
(E) t-distributed stochastic neighbor embedding
(tSNE) analysis of Fluidigm gene expression data
acquired from single cells (30–58 cells/population).
Results are expressed as mean ± SD; Bp < 0.05,
Cp < 0.01, *p < 0.001.
See also Figures S4 and S5.to determine how defects in platelet production could affect
the genesis of the different MPP subsets (Figure 5B). We
confirmed the major decrease in HSCLT and HSCST in Mpl/
mice (Qian et al., 2007) and found a consistent 2-fold reduc-
tion in the numbers of MPP2 and all lineage-committed pro-
genitors with Meg activity including Pre-MegE, MkP, and
CMP (Figures 5B and S4B). In sharp contrast, the numbers of
MPP3, MPP4, and other progenitors devoid of Meg activity
remained unchanged. These results highlight the key contribu-
tion of the Meg-biased MPP2 to megakaryopoiesis, and sug-
gest that MPP3 and MPP4 are produced independently from
MPP2 by HSCLT. Finally, we transplanted MPP2, MPP3, and
MPP4 isolated from wild-type mice into sub-lethally irradiated
recipients to evaluate their ability to regenerate other MPP
subsets shortly after transplantation (Figure 5C). However,
despite injecting high cell numbers, we were unable to detect
production of donor-derived LSK cells in BM from any MPP
subsets, while in the same conditions HSCLT regenerated a40 Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc.robust LSK population within 14 days
post-transplantation (Figures 5C and
S4C). In contrast, after 10 days, we
observed strong production of donor-
derived GMPs from all MPP subsets,
which persisted 14 days after transplan-
tation for MPP2 and MPP3, but not
for MPP4, which, by then, was mostly
producing lymphoid-derived progeny
(Figure S4D). These results confirm
the enhanced production of GMPs by
myeloid-biased MPP2 and MPP3 and
demonstrate that no MPPs are able to
generate other MPPs in vivo. Taken
together, these experiments establish
a hierarchy where HSCs independently
generate all three types of lineage-
biased MPPs, but with faster productionof Meg-biased MPP2 over GM-biased MPP3 and lymphoid-
primed MPP4.
Molecular Priming at Steady State
To gain insights into the molecular pathways controlling the pro-
duction of these differentMPP subsets, we used a custom-made
Fluidigm dynamic PCR array platform to analyze the expression
of 57 genes in pools of 100 HSCLT, MPP2, MPP3, and MPP4
(Figure 5D). Importantly, we detected the expected changes
in expression of the surface markers Slamf1 (CD150), Cd48,
and Flt3 (Flk2) that define the identity of these populations (Fig-
ure S5A). Overall, we found a significant reduction in expression
of self-renewal genes in MPPs compared to HSCLT, which was
more pronounced in MPP3 than in MPP4 (Figure 5D), and was
confirmed at the protein level using cells isolated from Bmi1-
eGFP reporter mice (Figure S5B) (Hosen et al., 2007). We also
documented the Meg poising of MPP2, with maintenance of
Gata2 expression to levels similar to HSCLT, and the lymphoid
Figure 6. Contribution to Blood Regene-
ration
(A) Experimental scheme for in vivo blood
regeneration experiments. Donor HSCLT were
transplanted into sub-lethally irradiated congenic
recipients (2,000 HSCLT/mouse) and regeneration
of donor BM subsets was followed at 2 and
3 weeks post-transplantation and compared to
steady-state control (Ctrl) mice.
(B) Representative FACS plots of regenerating
BM subsets.
(C) Frequency of the indicated BM subsets (6–10
mice/group).
(D) Methylcellulose clonogenic assays for the
indicated populations (n = 1–4)
(E) PC analysis of Fluidigm gene expression data
from the indicated populations (8–12 pools of
100 cells/condition).
Results are expressed as mean ± SD or SEM (D);
Bp < 0.05, Cp < 0.01, *p < 0.001.
See also Figures S5 and S6.priming of MPP4, with induction of Rag1 and higher expression
of Ikzf1 (Ikaros) compared to HSCLT and other MPP subsets
(Figure 5D). In addition, both MPP3 and MPP4 showed clear
evidence of GM poising compared to HSCLT and MPP2, with
induction of Cebpa, Irf8, and Sfpi1 (Pu.1) gene expression and
protein levels as measured in cells isolated from Pu.1-eYFP
reporter mice (Figures 5D and S5B). Consistent with their active
cell-cycle status, all MPPs displayed higher expression levels
of specific G1 to S and G2 to M phase cyclin/CDK complex
genes compared to HSCLT and a major downregulation of the
quiescence-enforcer Cdkn1c (p57) (Figure S5C). All MPPs also
showed elevated expression levels of some DNA repair pathway
components, especially Rad51 and Rpa1 (Figure S5C). More-
over, we performed single cell analyses with the same Fluidigm
platform and investigated the 49 most robustly expressed genes
using PC analyses and t-distributed stochastic neighbor embed-
ding (tSNE) to pinpoint the key molecular drivers segregating
these different populations (Figures 5E and S5D). As expected,
Cd48, Slamf1, and Flt3 were all important for PC1 separation.Cell Stem Cell 17,In addition, Cebpa, Irf8, Ccne1/2 (cyclin
E1 and E2), and Rad51 emerged as
important drivers for both PC1 and PC2
separation, which together with Slamf1
distinguished MPP2 and MPP3 from
each other and separated them from
HSCLT and MPP4. Collectively, these
analyses demonstrate that, at steady
state, all three MPP subsets are part
of an actively proliferating continuum
of differentiation with molecular priming
toward their respective lineage biases
and, in the case of the most abundant
MPP4, persistence of a significant GM
poised alongside its lymphoid priming.
Contribution to Blood Regeneration
To understand how each MPP subset
emerges from HSCs and contributes toblood regeneration, we injected CD45.2 donor HSCLT into sub-
lethally irradiated CD45.1 congenic recipients and followed the
production of donor-derived BM populations at 2 and 3 weeks
post-transplantation (Figure 6A). Strikingly, at 2 weeks, both
MPP2 and MPP3 were massively expanded and accounted for
most of the reforming LSK compartment, with HSCLT and HSCST
being exceedingly rare and MPP4 just starting to be generated
(Figures 6B and 6C). By 3 weeks, this process began to revert,
with MPP2 and MPP3 contracting toward their steady-state
levels as HSCLT and MPP4 expanded. In addition, at 2 weeks,
all donor-derived BM cells were essentially myeloid, whereas
by 3 weeks, lymphopoiesis had recovered, with a BM lineage
composition becoming similar to steady-state levels (Figures
6C and S5E). Consistently, we observed a transient expansion
of GMPs at 2 weeks, with kinetics matching the initial burst of
MPP2/MPP3 expansion andmyeloid cell production (Figure 6C).
These results indicate that regenerating HSCs first produce
myeloid-biased MPPs to quickly establish myeloid output,
followed by lymphoid-primed MPP4 to rebuild the lymphoid35–46, July 2, 2015 ª2015 Elsevier Inc. 41
Figure 7. Myeloid-Biased MPPs Are a Tran-
sient Compartment of Myeloid Amplifica-
tion
(A) Experimental scheme for re-transplantation of
regeneratingHSCLT.DonorCD45.2HSCLT isolated
from primary recipients at 2 and 3 weeks post-
transplantation or fromCtrl mice were injected into
lethally irradiated secondary CD45.1 recipients
(100 HSCLT/mouse) together with 3 3 105 Sca-1-
depleted CD45.1 BM cells (4–13 mice/group).
(B) Engraftment over time in PB.
(C) Engraftment in BM HSCLT at 16 weeks post-
transplantation.
(D) Limit dilution analyses (LDA) of Ctrl (black) and
2 weeks post-transplantation (red) BM cells.
Dotted lines represent confidence intervals and
values the estimated HSC frequency.
(E) Fluidigm gene expression analyses of key self-
renewal determinant, surface marker, and cell-cy-
cle genes in regenerating HSCLT at 2 and 3 weeks
post-transplantation. Results are expressed as
mean (bar) and individual fold compared to steady-
state Ctrl HSCLT (8–12 pools of 100 cells/condi-
tion).
(F) Proliferation rates in mice pulsed for 1 hr with
EdU (n = 1–3).
(G) IL-1 and IL-6 levels in BM fluid (5 mice/group).
(H) Revised model of blood production at steady
state and in regenerating conditions.
Results are expressed as mean ± SD or SEM (F);
Bp < 0.05,Cp < 0.01, *p < 0.001.
See also Figure S7.lineages. Functional assessment in methylcellulose showed
similar plating efficiency and overall lineage distribution between
newly produced MPP subsets at 2 and 3 weeks, compared to
steady state (Figure 6D). In contrast, regenerating HSCLT at
2 weeks displayed profoundly impaired differentiation potential
in vitro, whichwas in large part recovered by 3weeks (Figure 6D).
WealsoperformedFluidigmgeneexpression analysesonpools
of100donor-derivedcells re-isolatedat2and3weekspost-trans-
plantation to gain a molecular understanding of this regeneration
process (Figures 6E and S6). PC analyses indicated that regener-
ating HSCLT and newly generated MPP2 preserved their overall
molecular identity, whereas MPP3 and MPP4 showed greater
dispersion,mainly reflectingmorepronouncedchanges inexpres-
sion levels of certain lineage commitment genes (Figure 6E). In
particular,Meg/E lineage determinantswere significantly downre-
gulated in MPP3 andMPP4, while being preserved in both HSCLT
andMPP2 (Figure S6). In addition,MPP4 showed changes in both
lymphoid lineage determinants, with transient upregulation of42 Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc.Rag1and Ikzf1at 2weeks, andGMlineage
determinants. In fact, we discerned two
reciprocal patterns of changes in myeloid
commitment genes in regenerating HSCLT
and newly produced MPP4. At 2 weeks,
both populations showed increased
expression of Pu.1 and Runx1 and
decreased expression of Cebpa and Irf8,
which completely reversed at 3 weeks
(Figure S6). In contrast, newly producedMPP2 and MPP3 displayed limited changes in GM lineage
determinants aside from increased expression of Irf8 at 3 weeks
and fluctuations in Hoxa9 expression. These results show
that MPP4 undergo a significant molecular reprogramming
during regeneration, whereas newly produced MPP2 and MPP3
are able to maintain a strongMeg and GM potential, respectively,
hence highlighting the stability of their intrinsic lineage priming.
Altogether, they identify MPP2/MPP3 as a compartment of
myeloid amplification emerging rapidly from regenerating HSCLT,
andsuggest that themolecular reprogrammingofMPP4also likely
contributes to the initial burst of myeloid cell production.
Functional Reprogramming in Regenerating HSCs
To further investigate the changes in self-renewal activity occur-
ring in regenerating HSCLT, we re-transplanted donor-derived
HSCLT isolated at 2 and 3 weeks post-transplantation into
lethally irradiated secondary recipients and compared their
engraftment to freshly isolated control HSCLT (Figure 7A).
Strikingly, both 2 and 3 week regenerating HSCLT showed a
nearly complete lack of reconstitution activity in PB output
and BM engraftment compared to control HSCLT (Figures
7B, 7C, and S7A). Limit dilution analyses performed with un-
fractionated BM cells directly confirmed the impaired engraft-
ment ability of 2 week regenerating HSCLT independently of
surface markers (Figures 7D and S7B). Both 2 and 3 week re-
generating HSCLT also clearly displayed an activated status,
characterized by decreased expression of the quiescence-en-
forcing transcription factors Foxo3a and Egr1, increased
expression of Slamf1 and the MPP markers Cd48 and Flt3,
and induction of the cell-cycle machinery with increased
expression of G2-to-M phase cyclin/CDK complex genes (Fig-
ure 7E). Short-term in vivo 5-ethynyl-20-deoxyuridine (EdU)
incorporation experiments directly confirmed the highly prolif-
erative status of 2 week regenerating HSCLT, which had essen-
tially returned to steady-state levels by 3 weeks (Figure 7F). In
fact, by 4 weeks post-transplantation, donor-derived HSCLT
had also restored normal engraftment ability in vivo and plating
activity in methylcellulose (Figures S7C and S7D). Finally, cyto-
kine array analyses showed minimal perturbation in cytokine
levels (including M-CSF and IL-1) except for increased IL-6
production in the BM cavity of transplanted mice (Figures 7G
and S7E; data not shown). Taken together, these results
demonstrate that regenerating HSCLT temporarily lose their
self-renewal activity as they overproduce myeloid-biased
MPPs, and only recover their normal engraftment when blood
homeostasis and adequate production of lymphoid-primed
MPP4 are restored.
DISCUSSION
Here, we show that the MPP compartment is composed of at
least two distinct subsets of myeloid-biased MPPs (i.e., MPP2
and MPP3), which work together with lymphoid-primed MPP4
to regulate blood production. We find that all three subsets of
lineage-biased MPPs are independently produced by HSCs,
but with different kinetics and at varying levels depending on
hematopoietic demands. We demonstrate that myeloid-biased
MPPs are important for maintaining blood homeostasis at
steady state, and for rebuilding the myeloid lineages in regener-
ative conditions. Taken together, our results support a model of
blood development that highlights the key role of the MPP
compartment, and places its various lineage-biased subsets
at the center stage of lineage specification. They also support
the idea that the HSC compartment is functionally plastic,
with HSCs committed to differentiation and supporting blood
regeneration temporarily losing their engraftment ability. This
updated scheme has important implications for understanding
HSC self-renewal and blood production in various physiological
contexts.
Competing Models of Blood Development
HSCs are extremely efficient at sustaining long-term multiline-
age hematopoietic reconstitution in vivo and are the only blood
cells amenable to single cell transplantation assays. In contrast,
the functional characterization of multipotent or lineage-
committed progenitors remains challenging due to their low
yield and transient output in transplantation assays, which pre-clude most clonal analyses except for the recent attempt at len-
tiviral barcoding of MPP4 (Naik et al., 2013). Consequently, cur-
rent models of blood development place significantly more
emphasis on HSC function as measured by transplantation
rather than on the activity of non-self-renewing MPPs to explain
lineage specification. In the ‘‘clonal composition’’ model, the
distinct patterns of blood reconstitution in single cell transplan-
tation assays are explained by selection of particular HSC
clones (Copley et al., 2012), and the myeloid bias associated
with old age by a shift in clonal dominance with over-represen-
tation of myeloid-biased HSCs (Beerman et al., 2010). Consis-
tent with this idea, myeloid-biased HSCs have been prospec-
tively identified based on Hoechst dye exclusion (Challen
et al., 2010) or high CD150 expression (Morita et al., 2010).
Both the ‘‘graded differentiation’’ and ‘‘myeloid bypass’’ models
directly argue against the existence of true MPPs and propose
instead either a gradual loss of lineage potential with differenti-
ation, starting with loss of Meg potential at the HSC stage
(Adolfsson et al., 2005) and dendritic cell (DC) potential at the
MPP4 stage (Naik et al., 2013), or the existence of long-lived
myeloid-restricted repopulating progenitors that produce
myeloid cells independently from other lineages (Yamamoto
et al., 2013). However, all these models are interpretations of
reconstitution patterns in transplanted mice, which are unlikely
to reflect HSC function and lineage specification in native condi-
tions as directly suggested by two recent lineage tracking
studies that both showed a limited contribution of HSCs to
ongoing hematopoiesis (Sun et al., 2014; Busch et al., 2015). It
is also clear that engraftment and quiescence are intrinsically
connected, and that more metabolically active MPP1 are less
engrafting than quiescent HSCs (Cabezas-Wallscheid et al.,
2014). However, it remains unclear whether MPP1 are truly
separable from HSCs or whether they represent a reversible
stage of HSC activation. This unfortunately cannot be directly
tested using transplantation approaches.
To reconcile these observations, we propose a ‘‘dynamic
model’’ of blood development in which the HSC compartment
is, in fact, composed of distinct subsets of quiescent, activated,
and lineage-primed HSCs that represent a continuum of
likely reversible states and encompass the currently described
HSCLT (HSC/MPP1) and HSCST/ITRC populations. In turn,
this plastic HSC compartment conveys lineage specification
through the independent production of distinct subsets of line-
age-biasedMPPs in proportions that are based on hematopoiet-
ic demands (Figure 7H). This differs substantially from the
prevailing views that consider HSCs solely as an engrafting
population rather than a continuum of functional activity, and
MPPs as a single linear progression of differentiation rather
than parallel pathways that independently control the output
of the myeloid and lymphoid lineages. The capacity of HSCs
to independently produce specific subsets of lineage-biased
MPPs is likely to contribute to the clonal heterogeneity observed
upon single cell transplantation. Hence, myeloid-biased HSCs
and long-lived myeloid-restricted repopulating progenitors
could reflect the reconstitution pattern of HSCs that are primed
to produce myeloid-biased MPP2 and MPP3, with balanced
HSCs reflecting the behavior of uncommitted HSCs and
lymphoid-biased HSCs of HSCs that are poised to produce
lymphoid-primed MPP4.Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc. 43
Parallel MPP Compartments
Our results considerably expand on the functional characteriza-
tion of the MPP compartment. We show that while fully multipo-
tent in permissive culture conditions, both myeloid-biasedMPPs
display specific lineage preferences (i.e., Meg for MPP2 and GM
for MPP3). We confirm these biases at the molecular level, with
lineage priming reflective of the dominant blood output for
each MPP subset, but otherwise only modest differences in their
global transcriptional networks as expected for multipotent pro-
genitors. In the case of the lymphoid-primed MPP4, it is also
likely that their strong GM poising directly contributes to their
ability to produce myeloid cells at steady state and to be quickly
reprogrammed toward exclusive myeloid output in regenerative
conditions. We validate these lineage biases in vivo by showing
that MPP2 and MPP3 are more efficient at producing GMPs
than MPP4, and by establishing the importance of MPP2 for
megakaryopoiesis using Mpl/ mice. Moreover, we show that
HSCs independently produce all MPP subsets, but at different
levels and with different kinetics as exemplified by the delayed
emergence of the lymphoid-primedMPP4 in regenerative condi-
tions and the faster production of the Meg-biased MPP2 in vitro.
This is interesting in the context of the strong Meg potential
described for HSCs further purified with Von Willebrand factor
(Sanjuan-Pla et al., 2013), which could directly reflect in vivo
enrichment of HSCs that are primed to produce Meg-biased
MPP2. Our results also indicate that Flk2 myeloid-biased
MPPs are produced independently of Flk2+MPP4, which contra-
dicts recent fate-mapping results suggesting that all blood cells
are derived from Flk2-expressing progenitors (Boyer et al.,
2011). However, because MPP2 and MPP3 both express Flk2
mRNA at low levels at steady state and at increasing levels
during regeneration, it is possible that the transgenic Flk2-Cre
used in these experiments is activated in these MPP subsets
despite their lack of Flk2 surface protein expression. Another
possibility is that the early window during which MPP2 and
MPP3 rebuild the myeloid lineage, before re-establishment of
homeostasis and the dominant contribution of Flk2+ MPP4,
has been missed in this study. It will therefore be important to
use additional in vivo tracking approaches, such as those
recently published in native conditions (Sun et al., 2014; Busch
et al., 2015), to precisely map the differentiation paths of these
MPP subsets.
Molecular Reprogramming in Regenerative Conditions
Consistent with their lineage biases and specific roles in myeloid
cell production, we show that the lineage programming of MPP2
and MPP3 remains largely unchanged during regeneration. In
contrast, HSCs and MPP4 show transient reprogramming of
their lineage fate, with altered expression of similar myeloid line-
age genes during blood regeneration. This is characterized by
downregulation of Cebpa/Irf8 and concomitant upregulation of
Runx1/Pu.1, suggesting that the rebalancing of these two sets
of transcription factors plays an important role in primingmyeloid
lineage output in regenerative conditions. Indeed, C/EBPa is
dispensable for regenerative ‘‘emergency’’ granulopoiesis (Hirai
et al., 2006), and its downregulation may represent a mechanism
to activate HSC proliferation (Ye et al., 2013). Recent evidence
also suggests that elevated levels of Pu.1, a direct target of
Runx1, are crucial for promoting rapid myeloid differentiation in44 Cell Stem Cell 17, 35–46, July 2, 2015 ª2015 Elsevier Inc.HSCs (Mossadegh-Keller et al., 2013). These reciprocal changes
could therefore enforce HSC proliferation and transiently favor
HSC differentiation along a myeloid-biased MPP pathway, with
decreased expression of Irf8 eventually limiting monocyte/DC
specification in the context of elevated Pu.1 activity (Tamura
and Ozato, 2002). The transient induction of this program in
MPP4 could directly enforce myeloid output in a population
that, despite its GM priming, is also beginning to upregulate
key lymphoid differentiation genes. The increased IL-6 levels
detected in the BM cavity of transplanted mice could be part
of this mechanism as IL-6 is known to reprogram MPP4 away
from lymphoid differentiation and to amplify myeloid
differentiation (Reynaud et al., 2011).
Implications for Blood Production
Our results support the idea that myeloid-biased MPPs serve as
a transient compartment of myeloid expansion that can be
rapidly activated by HSCs to ensure appropriate production
of myeloid cells (Figure 7H). They also demonstrate that regener-
ating HSCs temporarily lose self-renewal activity as they over-
produce myeloid-biased MPPs and rebuild the blood system,
a phenotype perhaps linked to their increased cell cycle activity,
activated metabolic status, and/or myeloid priming (Kohli
and Passegue´, 2014). This finding raises further caution about
defining HSC identity solely based on transplantation experi-
ments because regenerating HSCs do not perform well in this
assay despite being fully capable of maintaining blood produc-
tion over time. It also raises the interesting possibility that
increased CD150 expression observed in both poorly engrafting
myeloid-biased HSC clones (Morita et al., 2010; Beerman et al.,
2010) and regenerating HSCs is linked to the production of
myeloid-biased MPPs and is essentially a reflection of their
activated/primed status. It will now be interesting to explore
whether differential production of lineage-biased MPPs by
HSCs could account for other long-lasting changes in blood
production, such as the predominant lymphoid/GM output
of fetal hematopoiesis (Kawamoto, 2006); the GM skewing, im-
munosenescence, and anemia of the old blood system (Geiger
and Rudolph, 2009); or the aberrant overproduction of different
myeloid lineages in hematological malignancies (Tefferi and
Gilliland, 2007). It will also be exciting to determine whether
similar populations of myeloid-biased MPPs exist in humans.
In addition, one of the main complications of anti-cancer thera-
pies or BM transplantation protocols is their deleterious effect
on the blood system, leading to prolonged neutropenia and
increased risk for infections. It will therefore be compelling to
test whether HSC differentiation pathways can be manipulated
to favor production of specific lineage-biased MPPs and
thereby optimize blood recovery following hematopoietic injury
or rebalance lineage output in an aging or deregulated blood
system.
EXPERIMENTAL PROCEDURES
Mice and Flow Cytometry
Six- to 8-week-old CD45.2 C57Bl/6 wild-type or b-actin-Gfp (Forsberg et al.,
2006) mice were used as donors for cell isolation, and 8- to 12-week-old
CD45.1 C57Bl/6-Boy/J wild-type mice were used as recipients for cell
transplantation. Transplanted mice were given antibiotic-containing water
for 4 weeks. All mice were maintained at the University of California San
Francisco in accordance with Institutional Animal Care and Use Committee-
approved protocols. Staining and enrichment procedures for flow cytometry
were performed as previously described (Santaguida et al., 2009; Reynaud
et al., 2011). Cells were sorted on a fluorescence-activated cell sorting
(FACS) ARIAII and analyzed on an LSRII (Becton Dickinson) upon PI exclu-
sion of dead cells. Each population was double sorted to ensure maximum
purity.
In Vitro Analyses
Proliferation, BrdU incorporation, differentiation and OP9/OP9-DL1 co-culture
experiments, microarray analyses, and Fluidigm experiments were performed
as described in the Supplemental Experimental Procedures. Three to five inde-
pendent biological replicates were used for each population. Methylcellulose
and MegaCult assays were performed according to the manufacturer’s proto-
cols (Stem Cell Technologies).
In Vivo Analyses
Transplantations, lineage tracking, and CFU-S assay were performed as
previously described (Forsberg et al., 2006; Reynaud et al., 2011). Congenic
recipient mice (CD45.1) were either lethally (1,100 rad, split dose 3 hr apart)
or sub-lethally (950 rad, split dose 3 hr apart) irradiated. Purified donor cells
were injected into the retro-orbital plexus, and hematopoietic reconstitution
was monitored over time in the peripheral blood based on CD45.2 or GFP
expression. EdU incorporation experiments and cytokine analyses were
performed according to the manufacturer’s protocols (Life Technologies).
Statistics
All data are expressed as mean ± SD or SEM as indicated. The p values
were generated using unpaired Student’s t test or a Mann-Whitney u test
(Fluidigm) and considered significant when %0.05. N indicates the number
of independent experiments performed.ACCESSION NUMBERS
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